Posted by D. Daniel Sokol
Dirk Bergemann (Cowles Foundation, Yale University), Benjamin Brooks (Dept. of Economics, Princeton University) and Stephen Morris (Dept. of Economics, Princeton University) discuss The Limits of Price Discrimination
ABSTRACT: We analyze the welfare consequences of a monopolist having additional information about consumers’ tastes, beyond the prior distribution; the additional information can be used to charge different prices to different segments of the market, i.e., carry out “third degree price discrimination.” We show that the segmentation and pricing induced by the additional information can achieve every combination of consumer and producer surplus such that: (i) consumer surplus is non-negative, (ii) producer surplus is at least as high as profits under the uniform monopoly price, and (iii) total surplus does not exceed the efficient gains from trade. As well as characterizing the welfare impact of price discrimination, we examine the limits of how prices and quantities can change under price discrimination. We also examine the limits of price discrimination in richer environments with quantity discrimination and limited ability to segment the market.
Featured News
Federal Judge Signals Revisions Likely in DOJ Case Targeting Live Nation Monopoly
Jan 22, 2025 by
CPI
American Airlines and JetBlue Agree to $2 Million Legal Fee Settlement with U.S. States
Jan 22, 2025 by
CPI
Federal Judge Dismisses Class Action Alleging Inflated Yacht Commission Fees
Jan 22, 2025 by
CPI
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan